Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer.

Autor:	Batool SM; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Hsia T; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Beecroft A; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Lewis B; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Ekanayake E; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Rosenfeld Y; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Escobedo AK; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Gamblin AS; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Rawal S; Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA., Cote RJ; Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA., Watson M; Washington University School of Medicine, St. Louis, MO, USA., Wong DTW; University of California Los Angeles, Los Angeles, CA, USA., Patel AA; Yale University School of Medicine, New Haven, CT, USA., Skog J; Exosome Diagnostics, Waltham, MA 02451, USA., Papadopoulos N; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bettegowda C; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Castro CM; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lee H; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Srivastava S; Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA., Carter BS; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Balaj L; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: Balaj.Leonora@mgh.harvard.edu.
Jazyk:	angličtina
Zdroj:	Cell reports. Medicine [Cell Rep Med] 2023 Oct 17; Vol. 4 (10), pp. 101196. Date of Electronic Publication: 2023 Sep 18.
DOI:	10.1016/j.xcrm.2023.101196
Abstrakt:	Liquid biopsy, through isolation and analysis of disease-specific analytes, has evolved as a promising tool for safe and minimally invasive diagnosis and monitoring of tumors. It also has tremendous utility as a companion diagnostic allowing detection of biomarkers in a range of cancers (lung, breast, colon, ovarian, brain). However, clinical implementation and validation remains a challenge. Among other stages of development, preanalytical variables are critical in influencing the downstream cellular and molecular analysis of different analytes. Although considerable progress has been made to address these challenges, a comprehensive assessment of the impact on diagnostic parameters and consensus on standardized and optimized protocols is still lacking. Here, we summarize and critically evaluate key variables in the preanalytical stage, including study population selection, choice of biofluid, sample handling and collection, processing, and storage. There is an unmet need to develop and implement comprehensive preanalytical guidelines on the optimal practices and methodologies. Competing Interests: Declaration of interests L.B.’s spouse is an employee of BioTechne. L.B. also has patent applications related to blood-based assays. C.C. has a consulting relationship with Qiagen, Teladoc, InfiniteMD, and Aikili Biosciences; has a patent (co-inventor) Nano-Plasmonic Sensor for Exosome Detection (US 10557847); and C.C.’s spouse is an employee of Legend Bioscience. C.B. is a consultant for Depuy-Synthes, Bionaut Labs, Galectin Therapeutics, Privo Technologies, and Haystack Oncology. He is a co-founder of OrisDx and Belay Diagnostics. A.A.P. is a founder and shareholder of Binary Genomics, Inc., is an inventor and assignee of patents and patent applications related to ultrasensitive nucleic acid analysis technologies, receives research funding from AstraZeneca, and has served as an advisor or consultant for NuGen, NuProbe, and Kohlberg Kravis Roberts & Co. D.W. has equity in RNAmeTRIX Inc. and Liquid Diagnostics LLC. He is also scientific consultant to AIONco/Avellino. N.P. is co-founder of Thrive Earlier Detection, an Exact Sciences Company. He is a consultant to Thrive Earlier Detection and holds equity in Exact Sciences. He is founder of or consultants to and owns equity in ManaT Bio., Haystack Oncology, Neophore, CAGE Pharma, and Personal Genome Diagnostics. N.P. is also a consultant to Vidium. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu